Novocure Ltd Aktie
15,87 €
Deine Einschätzung
Novocure Ltd Aktie
Was spricht für und gegen Novocure Ltd in den nächsten Jahren?
Pro
Kontra
Rendite von Novocure Ltd im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Novocure Ltd | -2,19 % | 1,50 % | -2,22 % | -12,32 % | 11,17 % | -85,81 % | -77,95 % |
Ironwood Pharmaceuticals | 1,51 % | 6,32 % | 3,06 % | -51,03 % | -60,39 % | -60,39 % | -54,18 % |
Arrowhead Pharmaceuticals Inc. | 3,93 % | -1,60 % | -9,20 % | -28,99 % | -33,58 % | -66,10 % | -29,55 % |
Iovance Biotherapeutics Inc. | 2,91 % | 7,80 % | -4,03 % | 65,06 % | 17,24 % | -57,82 % | -51,39 % |
Kommentare
News
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
Novocure (NASDAQ: NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in newly diagnosed glioblastoma (ndGBM)
Novocure Announces Planned CEO Transition
Novocure (NASDAQ: NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure’s Chief Financial Officer (CFO), Ashley Cordova, will succeed
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024. William Doyle, Novocure’s Executive Chairman